Chugai Files an Application with MHLW for an Additional Indication of Tecentriq as an Adjuvant Treatment for NSCLC in Japan
Shots:
- The filing is based on the results from the P-III IMpower010 study assessing Tecentriq (1200mg- IV) vs BSC in 1-005 patients in a ratio (1:1) with Stage IB-IIIA NSCLC- following surgical resection and up to 4 cycles of adjuvant cisplatin-based CT
- Results: 34% reduction in risk of disease recurrence or death in people with PD-L1 expression compared with BSC while safety data were consistent with its known safety profile & no new safety signals were observed
- Additionally- ~50% of patients with early-stage lung cancer experience relapse following surgery. Tecentriq is the first cancer immunotherapy that showed efficacy for the adjuvant treatment of NSCLC
Ref: Chugai | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com